| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/10/2002 | WO2002036587A2 Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides |
| 05/10/2002 | WO2002036584A1 Cholesterol lowering benzo`b! thiophenes and benzo`d! isothiazoles |
| 05/10/2002 | WO2002036582A1 Stable pharmaceutical form of an anticancer drug |
| 05/10/2002 | WO2002036580A2 Benzoxazole lpaat- beta inhibitors and uses thereof |
| 05/10/2002 | WO2002036578A2 Triazine derivatives as lpaat-b inhibitors and uses thereof |
| 05/10/2002 | WO2002036576A1 Phthalazinone derivatives |
| 05/10/2002 | WO2002036574A1 Geldanamycin derivatives useful for the treatment of cancer |
| 05/10/2002 | WO2002036571A1 (7-(3-carboxyphenyl)-4-chloroisoquinolin-1-yl)guanidine |
| 05/10/2002 | WO2002036570A1 4-substituted quinolines as antitumor agents |
| 05/10/2002 | WO2002036564A1 Sulfonylamino substituted 3-(aminomethylide)-2-indolinones as cell proliferation inhibitors |
| 05/10/2002 | WO2002036561A1 Bis-heterocyclic compounds with antitumour and chemosensitising activity |
| 05/10/2002 | WO2002036553A2 Substituted alkanoic acids |
| 05/10/2002 | WO2002036547A1 Cyclopropanecarboxylic acid amide compounds and medicinal use thereof |
| 05/10/2002 | WO2002036174A1 Radio-labelled ferrite particles and methods for the manufacture and use thereof |
| 05/10/2002 | WO2002036171A1 Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors |
| 05/10/2002 | WO2002036161A2 Novel targeted compositions for diagnostic and therapeutic use |
| 05/10/2002 | WO2002036160A2 Method for obtaining antigenic structures enhancing specific cross reactivity |
| 05/10/2002 | WO2002036149A2 Methods for obtaining inhibitors of t-cell membrane protein (tirc7) ligand binding and uses thereof |
| 05/10/2002 | WO2002036146A2 Epitope-beta microglobulin polynucleotide for anti-cancer immunotherapy |
| 05/10/2002 | WO2002036145A2 Kahalalide f formulation |
| 05/10/2002 | WO2002036135A2 Compositions for antitumour treatment containing ecteinascidin 743 |
| 05/10/2002 | WO2002036110A2 Oral self-emulsifying formulations of pyranone protease inhibitors |
| 05/10/2002 | WO2002036075A2 Small molecule compositions for binding to hsp90 |
| 05/10/2002 | WO2002036073A2 Receptor antagonist-lipid conjugates and delivery vehicles containing same |
| 05/10/2002 | WO2002036072A2 Method for short-term and long-term drug dosimetry |
| 05/10/2002 | WO2002016338A8 Aminoalkenylbenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same |
| 05/10/2002 | WO2002012238A3 2-(4-PYRIDYL)AMINO-6-DIALKOXYPHENYL-PYRIDO[2,3-d]PYRIMIDIN-7-ONES |
| 05/10/2002 | WO2002011743B1 Treatment of prostate cancer |
| 05/10/2002 | WO2002008200A3 Arylethene-sulfonamides, their preparation and their use as endothelin antagonists |
| 05/10/2002 | WO2002000821A3 A novel polypeptide, a human protein plp39 and the polynucleotide encoding the polypeptide |
| 05/10/2002 | WO2001096525A3 A novel polypeptide, a pogo conversion unit 18 and the polynucleotide encoding the polypeptide |
| 05/10/2002 | WO2001090316A3 Human circulating dendritic cell compositions and methods |
| 05/10/2002 | WO2001089564A3 Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity |
| 05/10/2002 | WO2001089282A3 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives |
| 05/10/2002 | WO2001088116A3 Method of modulating activation of lymphocytes via modulation of pituitary tumor transforming gene, related screeining methods |
| 05/10/2002 | WO2001083750A3 Dendritic cell co-stimulator molecules |
| 05/10/2002 | WO2001081342A3 Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use |
| 05/10/2002 | WO2001079469A3 Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses |
| 05/10/2002 | WO2001079288A3 Cytokine uses; compositions; methods |
| 05/10/2002 | WO2001078710A3 Paclitaxel treatment regimen for metastatic melanoma |
| 05/10/2002 | WO2001077145A3 Integrin binding peptide derivatives |
| 05/10/2002 | WO2001074845A3 Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof |
| 05/10/2002 | WO2001070808A3 Angiogenesis - associated proteins, and nucleic acids encoding the same |
| 05/10/2002 | WO2001068697A3 Methods and compositions for immunoregulation |
| 05/10/2002 | WO2001068677A3 Derivatives of breast canacer antigen her-2 for therapeutical use |
| 05/10/2002 | WO2001068135A3 Compositions and methods for affecting osteogenesis |
| 05/10/2002 | WO2001068034B1 1, 2, 4-triazoloribonucleoside prodrugs and their administration to treat viral disease conditions |
| 05/10/2002 | WO2001066742A3 G-protein coupled receptors |
| 05/10/2002 | WO2001066594A3 Human protein kinases and protein kinase-like enzymes |
| 05/10/2002 | WO2001064879A3 G-proteins coupled receptor related polypeptides |
| 05/10/2002 | WO2001064650A3 Synthesis of epothilones, intermediates thereto and analogues thereof |
| 05/10/2002 | WO2001064251A3 Combination chemotherapy |
| 05/10/2002 | WO2001064236A3 METHODS FOR TREATING FSH RELATED CONDITIONS WITH GnRH ANTAGONISTS |
| 05/10/2002 | WO2001064214A3 Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors |
| 05/10/2002 | WO2001051087A3 Novel treatment for eye disease |
| 05/10/2002 | WO2001049281A3 POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES |
| 05/10/2002 | WO2001048190A3 Therapeutic uses of lna-modified oligonucleotides |
| 05/10/2002 | WO2001042472A3 DNA ENCODING A NOVEL PROST-Ets POLYPEPTIDE |
| 05/10/2002 | WO2001041768A3 Use of hymenialdisine or derivatives thereof in the manufacture of medicaments |
| 05/10/2002 | WO2001040142A3 P21 derived peptides capable of inhibiting cdk/cyclin complexes |
| 05/10/2002 | WO2001038324A3 Imidazole derivatives and their use as raf kinase inhibitors |
| 05/10/2002 | WO2001036638A3 Polypeptides and nucleic acids encoding same |
| 05/10/2002 | WO2001036487A3 Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
| 05/10/2002 | WO2001036486A3 Scfv antibodies against disease associated molecules |
| 05/10/2002 | WO2001036433A3 Synthetic lipid-a analogs and uses thereof |
| 05/10/2002 | WO2001035990A3 Method for enhancing t cell reactivity toward tumour antigens |
| 05/10/2002 | WO2001034157A9 Protease inhibitors |
| 05/10/2002 | WO2001034131A3 Combination chemotherapy |
| 05/10/2002 | WO2001034117A9 A method for chemoprevention of prostate cancer |
| 05/10/2002 | WO2001032709A3 Polypeptides with non-natural primary signalling motifs |
| 05/10/2002 | WO2001032155A3 Use of egfr tyrosine kinase inhibitors for treating breast cancer |
| 05/10/2002 | WO2001031007A9 Nucleic acid molecules derived from rat brain and programmed cell death models |
| 05/10/2002 | WO2001028580A3 Modulation of angiogenesis |
| 05/10/2002 | WO2001027146A9 Chemokine receptor |
| 05/10/2002 | WO2001027135A3 Regulators of the hedgehog pathway, compositions and uses related thereto |
| 05/10/2002 | WO2001026629A3 Neutral-cationic lipid for nucleic acid and drug delivery |
| 05/10/2002 | WO2001025271A3 Fibroblast growth factor-5 (fgf-5) is a tumor associated t-cell antigen |
| 05/10/2002 | WO2001023386A3 Benzodiazepin derivatives, the production and use thereof |
| 05/10/2002 | WO2000073349A9 Dr4 antibodies and uses thereof |
| 05/10/2002 | WO2000067761A8 Compositions and methods for identifying antigens which elicit an immune response |
| 05/10/2002 | WO2000058339A3 50 human secreted proteins |
| 05/10/2002 | WO2000054802A3 Method of expressing antigens on the surface of antigen presenting cells by photochemical internalization |
| 05/10/2002 | WO2000050639A3 Gene sequence variations with utility in determining the treatment of disease |
| 05/10/2002 | WO2000042208A8 Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use |
| 05/10/2002 | CA2463623A1 Epitope-beta microglobulin polynucleotide for anti-cancer immunotherapy |
| 05/10/2002 | CA2428606A1 Novel targeted compositions for diagnostic and therapeutic use |
| 05/10/2002 | CA2427952A1 Dna expression vectors |
| 05/10/2002 | CA2427850A1 Interferons, uses and compositions related thereto |
| 05/10/2002 | CA2427802A1 Methods and compositions for the diagnosis of cancer susceptibilites and defective dna repair mechanisms and treatment thereof |
| 05/10/2002 | CA2427800A1 Prokineticin polypeptides, related compositions and methods |
| 05/10/2002 | CA2427613A1 (7-(3-carboxyphenyl)-4-chloroisoquinolin-1-yl)guanidine |
| 05/10/2002 | CA2427572A1 Immunomodulatory peptides derived from heat shock proteins and uses thereof |
| 05/10/2002 | CA2427568A1 Tricyclic derivatives of indole with antiangiogenic activity |
| 05/10/2002 | CA2427565A1 Bis-heterocyclic compounds with antitumour and chemosensitising activity |
| 05/10/2002 | CA2427539A1 Method for obtaining antigenic structures enhancing specific cross reactivity |
| 05/10/2002 | CA2427518A1 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 05/10/2002 | CA2427194A1 Method for short-term and long-term drug dosimetry |
| 05/10/2002 | CA2427130A1 Radio-labelled ferrite particles and methods for the manufacture and use thereof |
| 05/10/2002 | CA2426762A1 Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors |
| 05/10/2002 | CA2425627A1 Kahalalide f |